Compare Elastic NV (ESTC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Neurocrine Biosciences Inc — how do they compare? Elastic NV trades at $98.4 (market cap $10.00B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Elastic NV is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Neurocrine Biosciences Inc for 23 Days on average.
| ESTC | NBIX | |
|---|---|---|
Market Cap | $10.00B | $14.36B |
Volume | 1,610,337 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $99.91 | $185.50 |
52-Week Low | $43.30 | $123.10 |
Typical Hold Time | 10 Days | 23 Days |
Enterprise Value | $9.14B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $98.23, up 5.51% today, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent product launches, including AI-driven metrics and serverless vector database offerings, highlight innovation in observability and search. Revenue growth is projected to increase from $1.48B in 2025 to $1.8B in 2026, with net income turning positive to $376M.
The outlook is positive given earnings momentum and strategic product expansions, though high valuation ratios and insider selling pose risks. The consensus price target of $79.50 suggests potential downside from current levels, but bullish technicals and institutional interest support a constructive view. Key risks include competitive pressures and execution challenges in scaling new AI integrations.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
